Cargando…
Clinical outcomes of hospitalized COVID-19 patients with renal injury: a multi-hospital observational study from Wuhan
Renal injury is common in patients with coronavirus disease 2019 (COVID‐19). We aimed to determine the relationship of estimated glomerular filtration rate (eGFR) and acute kidney injury (AKI) with the characteristics, progression, and prognosis of COVID-19 in-patients. We retrospectively reviewed 1...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313555/ https://www.ncbi.nlm.nih.gov/pubmed/34312430 http://dx.doi.org/10.1038/s41598-021-94570-1 |
_version_ | 1783729374247256064 |
---|---|
author | Chen, Kehong Lei, Yu He, Yani Xiao, Fei Yu, Yan Lai, Xiaodong Liu, Yang Wang, Jiang Dai, Huanzi |
author_facet | Chen, Kehong Lei, Yu He, Yani Xiao, Fei Yu, Yan Lai, Xiaodong Liu, Yang Wang, Jiang Dai, Huanzi |
author_sort | Chen, Kehong |
collection | PubMed |
description | Renal injury is common in patients with coronavirus disease 2019 (COVID‐19). We aimed to determine the relationship of estimated glomerular filtration rate (eGFR) and acute kidney injury (AKI) with the characteristics, progression, and prognosis of COVID-19 in-patients. We retrospectively reviewed 1851 COVID-19 patients admitted to 3 hospitals in Wuhan, China. Clinical, laboratory, radiological, treatment, complication, and outcome data were analyzed. Patients were stratified according to levels of eGFR (≥ 90 vs. 60–89 vs. < 60 mL/min/1.73 m(2)). The risk of reaching the composite endpoint—intensive care unit admission, invasive ventilation, or death—was compared. On admission, 25.5% patients had renal impairment (eGFR < 90 mL/min/1.73 m(2)), but only 2.6% patients had chronic kidney disease (CKD). The overall in-hospital AKI incidence was 6.7%. Severe illness and comorbidities (hypertension, diabetes, CKD, and cardiovascular/cerebrovascular diseases) were more common among patients with low eGFR (< 90 mL/min/1.73 m(2)). Despite the more frequent use of intensive oxygen therapy, continuous blood purification, and glucocorticoid treatment, the prognosis of these patients was unsatisfactory, with the incidence of the composite endpoint (15.4% vs. 19.6% vs. 54.5%; P = 0.000) and complications (AKI, respiratory failure, cardiac injury, coagulation disorders, sepsis, etc.) increasing with decreasing eGFR. Kaplan–Meier survival analysis revealed that patients with eGFR < 90 mL/min/1.73 m(2) or AKI had significantly escalated risks of reaching the composite endpoint. Multivariate regression analysis showed that renal insufficiency (eGFR < 60 mL/min/1.73 m(2)) on admission and in-hospital AKI independently predicted poor prognosis among COVID-19 in-patients. And renal impairment on admission was a greater predictor of poor prognosis in non-elderly patients than that in elderly patients. Early and continuous renal-function monitoring and early AKI diagnosis are necessary to predict and prevent the progression of COVID-19. |
format | Online Article Text |
id | pubmed-8313555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-83135552021-07-27 Clinical outcomes of hospitalized COVID-19 patients with renal injury: a multi-hospital observational study from Wuhan Chen, Kehong Lei, Yu He, Yani Xiao, Fei Yu, Yan Lai, Xiaodong Liu, Yang Wang, Jiang Dai, Huanzi Sci Rep Article Renal injury is common in patients with coronavirus disease 2019 (COVID‐19). We aimed to determine the relationship of estimated glomerular filtration rate (eGFR) and acute kidney injury (AKI) with the characteristics, progression, and prognosis of COVID-19 in-patients. We retrospectively reviewed 1851 COVID-19 patients admitted to 3 hospitals in Wuhan, China. Clinical, laboratory, radiological, treatment, complication, and outcome data were analyzed. Patients were stratified according to levels of eGFR (≥ 90 vs. 60–89 vs. < 60 mL/min/1.73 m(2)). The risk of reaching the composite endpoint—intensive care unit admission, invasive ventilation, or death—was compared. On admission, 25.5% patients had renal impairment (eGFR < 90 mL/min/1.73 m(2)), but only 2.6% patients had chronic kidney disease (CKD). The overall in-hospital AKI incidence was 6.7%. Severe illness and comorbidities (hypertension, diabetes, CKD, and cardiovascular/cerebrovascular diseases) were more common among patients with low eGFR (< 90 mL/min/1.73 m(2)). Despite the more frequent use of intensive oxygen therapy, continuous blood purification, and glucocorticoid treatment, the prognosis of these patients was unsatisfactory, with the incidence of the composite endpoint (15.4% vs. 19.6% vs. 54.5%; P = 0.000) and complications (AKI, respiratory failure, cardiac injury, coagulation disorders, sepsis, etc.) increasing with decreasing eGFR. Kaplan–Meier survival analysis revealed that patients with eGFR < 90 mL/min/1.73 m(2) or AKI had significantly escalated risks of reaching the composite endpoint. Multivariate regression analysis showed that renal insufficiency (eGFR < 60 mL/min/1.73 m(2)) on admission and in-hospital AKI independently predicted poor prognosis among COVID-19 in-patients. And renal impairment on admission was a greater predictor of poor prognosis in non-elderly patients than that in elderly patients. Early and continuous renal-function monitoring and early AKI diagnosis are necessary to predict and prevent the progression of COVID-19. Nature Publishing Group UK 2021-07-26 /pmc/articles/PMC8313555/ /pubmed/34312430 http://dx.doi.org/10.1038/s41598-021-94570-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Chen, Kehong Lei, Yu He, Yani Xiao, Fei Yu, Yan Lai, Xiaodong Liu, Yang Wang, Jiang Dai, Huanzi Clinical outcomes of hospitalized COVID-19 patients with renal injury: a multi-hospital observational study from Wuhan |
title | Clinical outcomes of hospitalized COVID-19 patients with renal injury: a multi-hospital observational study from Wuhan |
title_full | Clinical outcomes of hospitalized COVID-19 patients with renal injury: a multi-hospital observational study from Wuhan |
title_fullStr | Clinical outcomes of hospitalized COVID-19 patients with renal injury: a multi-hospital observational study from Wuhan |
title_full_unstemmed | Clinical outcomes of hospitalized COVID-19 patients with renal injury: a multi-hospital observational study from Wuhan |
title_short | Clinical outcomes of hospitalized COVID-19 patients with renal injury: a multi-hospital observational study from Wuhan |
title_sort | clinical outcomes of hospitalized covid-19 patients with renal injury: a multi-hospital observational study from wuhan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313555/ https://www.ncbi.nlm.nih.gov/pubmed/34312430 http://dx.doi.org/10.1038/s41598-021-94570-1 |
work_keys_str_mv | AT chenkehong clinicaloutcomesofhospitalizedcovid19patientswithrenalinjuryamultihospitalobservationalstudyfromwuhan AT leiyu clinicaloutcomesofhospitalizedcovid19patientswithrenalinjuryamultihospitalobservationalstudyfromwuhan AT heyani clinicaloutcomesofhospitalizedcovid19patientswithrenalinjuryamultihospitalobservationalstudyfromwuhan AT xiaofei clinicaloutcomesofhospitalizedcovid19patientswithrenalinjuryamultihospitalobservationalstudyfromwuhan AT yuyan clinicaloutcomesofhospitalizedcovid19patientswithrenalinjuryamultihospitalobservationalstudyfromwuhan AT laixiaodong clinicaloutcomesofhospitalizedcovid19patientswithrenalinjuryamultihospitalobservationalstudyfromwuhan AT liuyang clinicaloutcomesofhospitalizedcovid19patientswithrenalinjuryamultihospitalobservationalstudyfromwuhan AT wangjiang clinicaloutcomesofhospitalizedcovid19patientswithrenalinjuryamultihospitalobservationalstudyfromwuhan AT daihuanzi clinicaloutcomesofhospitalizedcovid19patientswithrenalinjuryamultihospitalobservationalstudyfromwuhan |